MX2022011002A - Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. - Google Patents

Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.

Info

Publication number
MX2022011002A
MX2022011002A MX2022011002A MX2022011002A MX2022011002A MX 2022011002 A MX2022011002 A MX 2022011002A MX 2022011002 A MX2022011002 A MX 2022011002A MX 2022011002 A MX2022011002 A MX 2022011002A MX 2022011002 A MX2022011002 A MX 2022011002A
Authority
MX
Mexico
Prior art keywords
antibodies
humanized
chimeric
treatment
relates
Prior art date
Application number
MX2022011002A
Other languages
English (en)
Inventor
Janine Schuurman
Patrick Engelberts
Rik Rademaker
Isil Altintas
Paul Parren
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/050296 external-priority patent/WO2016110576A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of MX2022011002A publication Critical patent/MX2022011002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se relaciona con anticuerpos humanizados o quiméricos que unen CD3. Adicionalmente se relaciona con anticuerpos biespecíficos, composiciones, composiciones farmacéuticas, uso de los anticuerpos en el tratamiento de una enfermedad y método de tratamiento.
MX2022011002A 2015-07-15 2018-01-09 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. MX2022011002A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201500413 2015-07-15
DKPA201500414 2015-07-15
DKPA201500416 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20

Publications (1)

Publication Number Publication Date
MX2022011002A true MX2022011002A (es) 2022-10-07

Family

ID=57757079

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000347A MX2018000347A (es) 2015-07-15 2016-07-14 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2022011002A MX2022011002A (es) 2015-07-15 2018-01-09 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000347A MX2018000347A (es) 2015-07-15 2016-07-14 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.

Country Status (14)

Country Link
US (4) US11359015B2 (es)
EP (1) EP3322727A1 (es)
JP (2) JP2018526981A (es)
KR (1) KR20180030635A (es)
CN (2) CN108368172B (es)
AU (2) AU2016293073B2 (es)
BR (1) BR112018000696A2 (es)
CA (1) CA2992380A1 (es)
EA (1) EA201890305A1 (es)
IL (2) IL310467A (es)
MX (2) MX2018000347A (es)
NZ (1) NZ739028A (es)
UA (1) UA128057C2 (es)
WO (1) WO2017009442A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
US10465006B2 (en) 2013-07-05 2019-11-05 Genmab A/S Humanized or chimeric CD3 antibodies
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
WO2018162749A1 (en) 2017-03-09 2018-09-13 Genmab A/S Antibodies against pd-l1
US11668021B2 (en) 2017-05-09 2023-06-06 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN110831965B (zh) 2017-06-21 2023-03-07 吉利德科学公司 靶向hiv gp120和cd3的多特异性抗体
MA52152A (fr) 2018-03-12 2021-01-20 Genmab As Anticorps
WO2019175658A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
EP3973000A4 (en) * 2019-06-07 2023-09-06 Adimab, LLC HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHODS OF GENERATION AND USE THEREOF
KR20220113346A (ko) * 2019-07-29 2022-08-12 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 칸디다에 대한 항체 및 이의 용도
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
CR20220521A (es) 2020-03-18 2023-01-23 Genmab As Anticuerpos
KR20230008775A (ko) * 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
JP2023541860A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
EP4221742A1 (en) 2020-10-02 2023-08-09 Genmab A/S Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
KR20240004949A (ko) 2021-05-07 2024-01-11 젠맵 에이/에스 B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
US11814437B2 (en) 2021-10-08 2023-11-14 Genmab A/S Antibodies binding to CD30 and CD3

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
LT2520590T (lt) 2007-04-03 2018-09-10 Amgen Research (Munich) Gmbh Susijusioms rūšims specifinis rišantis domenas
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SI2786762T1 (sl) 2008-12-19 2019-07-31 Macrogenics, Inc. Kovalentna diatelesa in njihove uporabe
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN103796677B (zh) 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
CN104114579B (zh) 2011-10-27 2020-01-24 健玛保 异二聚体蛋白的生成
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
CA2915412A1 (en) * 2012-06-14 2013-12-19 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
EP2895203A4 (en) 2012-06-15 2016-09-28 Imaginab Inc ANTIGEN BINDING CONSTRUCTIONS FOR CD3
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
ES2758979T3 (es) 2012-07-06 2020-05-07 Genmab Bv Proteína dimérica con mutaciones triples
JP6144771B2 (ja) 2012-11-21 2017-06-07 ファームアブシン インコーポレイテッド Ｖｅｇｆｒ−２とｄｌｌ４を標的とする二重標的抗体及びこれを含む薬学的組成物
US10465006B2 (en) 2013-07-05 2019-11-05 Genmab A/S Humanized or chimeric CD3 antibodies
AU2016205967B2 (en) 2015-01-08 2021-11-11 Genmab A/S Bispecific antibodies against CD3 and CD20

Also Published As

Publication number Publication date
US20220389101A1 (en) 2022-12-08
AU2016293073B2 (en) 2022-12-22
JP2018526981A (ja) 2018-09-20
IL256562B1 (en) 2024-03-01
JP2022023862A (ja) 2022-02-08
AU2016293073A1 (en) 2018-02-01
US11359015B2 (en) 2022-06-14
US20190284278A1 (en) 2019-09-19
BR112018000696A2 (pt) 2018-09-18
NZ739028A (en) 2023-05-26
IL310467A (en) 2024-03-01
CA2992380A1 (en) 2017-01-19
WO2017009442A1 (en) 2017-01-19
UA128057C2 (uk) 2024-03-27
US20230027394A1 (en) 2023-01-26
KR20180030635A (ko) 2018-03-23
CN108368172B (zh) 2022-06-14
CN108368172A (zh) 2018-08-03
IL256562A (en) 2018-02-28
US20220380464A1 (en) 2022-12-01
MX2018000347A (es) 2018-03-14
CN114989302A (zh) 2022-09-02
EA201890305A1 (ru) 2018-07-31
AU2023201733A1 (en) 2023-07-13
EP3322727A1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2022002364A (es) Anticuerpos anti-pd-l1.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
NZ738008A (en) Tigit-binding agents and uses thereof
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
NZ766356A (en) Anti-pd-1 antibodies
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12016501366A1 (en) Novel anti-baff antibodies
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
NZ739560A (en) Novel anti-human gpvi antibodies and uses thereof
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.